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Abstract 1 
Background: Total energy expenditure (TEE) data in patients with earlier stage cancer 2 
is scarce, precluding an understanding of energy requirements. 3 
Objective: The objective was to cross-sectionally characterize TEE in patients with 4 
colorectal cancer (CRC) and to compare measured TEE to energy intake recommendations. It 5 
was hypothesized that TEE would differ according to body mass, body composition, and 6 
physical activity level (PAL) and current energy recommendations would have poor individual-7 
level accuracy. 8 
Design: Patients with newly-diagnosed CRC had resting energy expenditure (REE) measured by 9 
indirect calorimetry and TEE by doubly labeled water. Hypermetabolism was defined as REE > 10 
110% predicted from the Mifflin St.-Jeor equation. Body composition was assessed via dual X-11 
ray absorptiometry. Physical activity was determined as the ratio TEE:REE (PAL) and residual 12 
activity energy expenditure (RAEE). TEE was compared to energy recommendations of 25-30 13 
kcal/day and dietary reference intakes (DRI) using Bland-Altman analyses. Patients were 14 
stratified according to median body mass index (BMI), PAL, and sex-specific fat mass (FM) to 15 
fat-free mass (FFM) ratio (FM:FFM). 16 
Results: Twenty-one patients (M:F 14:7; BMI: 28.3±4.9kg/m2, age: 57±12years) were included. 17 
Most (n=20) had stage II-III disease; 1 had stage IV. Approximately half (n=11) were 18 
hypermetabolic; TEE was not different in those with hypermetabolism and REE was not 19 
correlated to TEE. TEE was 2473±499 kcal/day (range: 1562, 3622 kcal/day), or 29.7±6.3 20 
kcal/kg body weight (range: 20.4, 48.5). Average PAL was 1.43±0.27. Energy recommendation 21 
of 25 kcal/kg underestimated TEE (-12.6±16.5%, P = 0.002); all energy recommendations had 22 
wide limits of agreement (smallest was DRI: -21.2, 29.3%). Patients with higher BMI and 23 
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FM:FFM had higher bias using kcal/kg recommendations; bias from several recommendations 24 
was frequently lower in patients with higher PAL and RAEE. 25 
Conclusions: TEE variability was not reflected in energy recommendations and error 26 
was influenced by body weight, body composition, and physical activity. 27 
Key words: Energy expenditure, energy metabolism, cancer, energy requirements, energy 28 
balance, nutritional assessment, dietary intake, body composition, physical activity 29 
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Introduction: 47 
Energy balance is the long-term relationship between energy intake and total energy 48 
expenditure (TEE; sum of energy required for bodily maintenance at rest, movement, and food 49 
digestion, absorption, and transport). Characterizing TEE is therefore essential for understanding 50 
energy requirements needed to support or modulate energy balance. This concept is especially 51 
relevant for individuals with cancer since body weight and body composition changes (i.e. loss 52 
of fat-free mass, FFM) can be detrimental to prognosis (1–3). Conversely, weight gain during 53 
cancer treatment may not confer a survival advantage in some circumstances (1), might worsen 54 
pre-existing comorbidities, and increase secondary disease risk in patients with obesity (4,5).  55 
 In oncology, most of our understanding of energy expenditure comes from studies of 56 
resting energy expenditure (REE), which is the largest component of TEE in non-athletic 57 
populations. However, in patients with cancer, REE might be affected by changes in body 58 
composition, systemic inflammation or tumor burden and may not correlate to TEE (6). Since the 59 
ratio of TEE to REE is indicative of physical activity level (PAL), absence of a relationship 60 
between REE and TEE indicates that variable physical activity might impact TEE within this 61 
population, rather than REE alone. 62 
To date, only four reports have measured TEE in cancer using objective and accurate 63 
techniques such as doubly labeled water (DLW) or bicarbonate-urea (6–9), which severely limits 64 
current understanding of energy requirements in oncology settings. The majority of patients in 65 
these previous studies had advanced (i.e. stage IV) disease (6) or severe weight loss (i.e. 19% of 66 
pre-illness body weight)(7). However, this likely represents a small proportion of patients with 67 
certain types of cancer. For example, colorectal cancer (CRC) is the third most commonly 68 
diagnosed cancer in the World (10); improvements in screening practices, lower incidence of risk 69 
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factors, and effective treatments options has led to a higher proportion of cancer cases diagnosed 70 
at earlier stages (11), where severe wasting/weight loss (i.e. cachexia (12)) and high systemic 71 
inflammation is less common (13). These patients also have a high prevalence of obesity at 72 
diagnosis and weight gain during curative-intent treatment (14). 73 
Due the paucity of data characterizing TEE in patients with cancer, current oncology 74 
energy intake recommendations are based on an estimate of 25-30 kcal/kg body weight with a 75 
call for further research (15). However, basing recommendations on body weight alone would 76 
likely overestimate energy requirements in individuals with obesity and underestimate it in those 77 
with low body weight (16). Furthermore, such recommendations do not consider body 78 
composition, physical activity, cancer type, or disease stage, which might impact TEE.  79 
 The objectives of the current study were to compare TEE to current energy 80 
recommendations and to characterize TEE in relation to body weight, body composition, and 81 
physical activity. It was hypothesized that current energy recommendations would have poor 82 
individual-level accuracy and TEE would differ according to body mass, body composition, and 83 
PAL categories.  84 
Methods: 85 
Study and subjects 86 
This analysis is part of a larger cross-sectional study measuring energy expenditure, body 87 
composition, physical activity and dietary intake in patients with cancer (17). Patients with stage 88 
II-IV CRC were recruited from the Cross Cancer Institute in Edmonton, Alberta, Canada. In line 89 
with common practice in gastrointestinal oncology, patients with stage II or III CRC were 90 
considered to have “early stage” disease. In addition, patients with lympho-vascular invasion, T4 91 
tumor size, gastrointestinal obstruction, or high tumor grade were considered to have a high risk 92 
7 
 
for recurrence and were advised to undergo surgical removal of the tumor. Recruitment for the 93 
full ongoing trial began in April 2016; between March 2017 and January 2018, patients were 94 
offered additional TEE and body composition assessments. This study was approved by the 95 
Health Research Ethics Board of Alberta and informed consent was obtained from all patients 96 
prior to study assessments. Inclusion criteria were recent cancer diagnosis, aged 18-90 years, and 97 
able to communicate freely in English. Exclusion criteria included anti-cancer therapy or surgery 98 
within the past four weeks, confinement to a wheelchair, medications or conditions that might 99 
affect body composition or metabolism (steroids, hormone replacement, unstable thyroid 100 
disease), inability to breathe under the calorimetry hood for 30 minutes, pregnancy, or 101 
breastfeeding. All measurements were completed within (before or after) two weeks of starting 102 
anti-cancer therapy, where applicable.  103 
Patient-reported measures 104 
Individuals in this study were asked to complete several profiling questionnaires. Patients 105 
completed the Patient-Generated Subjective Global Assessment (PG-SGA) – short form (18), 106 
which consists of four sections: weight (score range: 0 – 5), food intake (score range: 0 – 4) 107 
symptoms (score range: 0 – 24), and activities and function (score range: 0 – 3). Lower scores 108 
indicate better results in each section. The European Organization for the Research and 109 
Treatment of Cancer Quality of Life Questionnaire – C30 (version 3.0) (19) was also completed; 110 
only overall quality of life score (range: 1 – 7) was used in this analysis, with higher scores 111 
representing better quality of life. The International Physical Activity Questionnaire – Long 112 
Form (IPAQ) (20) was used to measure subjective physical activity; continuous values from the 113 
IPAQ were expressed as metabolic equivalencies of tasks (MET) minutes/week.  114 
Anthropometry and body composition 115 
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 Height and weight were measured using a Health-O-Meter Professional digital scale with 116 
height rod (McCook, IL, USA; model number: 597KL) with shoes and heavy clothing removed. 117 
One-month and six-month previous weight change percent was collected from the PG-SGA. 118 
Body mass index (BMI) was calculated [weight (kg)/height (m2)] and classified according to the 119 
World Health Organization’s cut-points (21). 120 
 Body composition was assessed by dual X-ray absorptiometry (Lunar iDXA, GE 121 
Healthcare, Chicago, IL; Encore 2001 software version 13.60) within a median and standard 122 
error of 9 ± 3 days of energy expenditure assessments. Fat mass (FM) and fat-free mass (FFM) 123 
were expressed adjusting for height in m2 (fat mass index, FMI, and fat-free mass index, FFMI) 124 
and as a ratio (FM:FFM), to represent metabolic load and capacity as explained elsewhere (22).  125 
Percent body fat was also reported. Appendicular skeletal muscle index (ASMI) was calculated 126 
as the sum of lean soft tissue from limbs divided by height (kg/m2), with low ASMI defined as 127 
<5.45 kg/m2 for females and <7.26 kg/m2 for males (23). Similarly, FFMI <15 kg/m2 for females 128 
and <16 kg/m2 for males were used to define “myopenia” for exploratory purposes (24). 129 
Resting energy expenditure 130 
An indirect calorimeter with ventilated hood system (VMaxTM Spectra 29N, Nutritional 131 
Assessment Instrument; Sensor-Medics, Yorba Linda, CA, USA) was used to measure REE. 132 
This particular system is considered one of the most accurate metabolic carts (25) and has been 133 
used as a gold standard in previous studies (26,27). Volume and air flow were calibrated prior to 134 
each measurement using a three-liter syringe. Gas analysers were calibrated before each test with 135 
standard gas concentrations of 20.95% oxygen (O2) and 0.03% carbon dioxide (CO2). Fraction of 136 
expired carbon dioxide was kept between 0.75 and 0.80 for as much time as possible. Breath 137 
samples were collected for 30 minutes and only steady state data (variations in volume of O2 and 138 
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CO2 of ≤ 10% over five consecutive minutes) was used. The abbreviated Weir equation (28) was 139 
used to calculate REE. Respiratory quotient was calculated as the ratio between carbon dioxide 140 
produced and oxygen consumed (CO2/O2). Measured REE was compared to predicted REE to 141 
identify high or low REE, or hyper- or hypo-metabolism, respectively. The Mifflin St.-Jeor 142 
equation was used for predicted REE since it predicts REE with the most accuracy (29).  143 
Total energy expenditure 144 
TEE was the primary outcome of this investigation and was assessed using DLW over 14 145 
days. Stock doses were formulated using 10 atom% oxygen 18 (18O) and 99.9 atom% deuterium 146 
(2H) based on 1g/kg 18O and 0.1 g/kg 2H of body weight per patient. A single baseline urine 147 
sample was collected before dosing (pre-dose). Patients drank the dose with a straw followed by 148 
~50mL tap water to rinse the dose cup; actual dose was therefore assumed to be the same as the 149 
dose given. All patients were asked to collect a urine sample 4.5 and 6 hours after dosing and 1-2 150 
times/day for the following 13 days. Only isotope enrichments from urine samples from pre-151 
dose, 4.5 and 6 hours post-dose, days 3, 7, and 14 were analyzed..  152 
Measurement of 2H2 and 18O isotope enrichments from stock doses and urine samples 153 
were analyzed by using a dual inlet chromium reduction and continuous flow isotope ratio mass 154 
spectrometer at the National Institutes of Health (Bethesda, MD, USA). Natural logarithms of 2H 155 
and 18O enrichments were regressed against time, with slopes of regression lines representing 156 
rates of 2H and 18O loss from body water (kH and kO, respectively). 2H and 18O dilution spaces 157 
(NH and NO, respectively) were determined by dividing administered isotopes (in moles) by the 158 
intercepts. Total body water was then calculated as (30,31): 159 
 160 
Total body water = 0.5 x (NO/cO + NH/cH) 161 
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 162 
Where cH and cO were the sizes of 2H and 18O pool sizes relative to total body water. To account 163 
for some isotopes entering organic pools, non-aqueous cH was assumed to be 1.041 and cO was 164 
assumed to be 1.007. The isotope fractionation for 2H leaving the body as water vapor is 0.946 165 
times the true rate of water it equilibrates with and the fractionation factor for 18O leaving the 166 
body as CO2 is 1.038 times the true rate of carbon dioxide production (32). We assumed breath 167 
was saturated with water vapor and non-sweat skin water vapour loss was proportional to 168 
exposed skin surface; therefore the simplified equation from the International Atomic Energy 169 
Agency (32) was used to calculated CO2 as follows: 170 
 171 
CO2 (moles) = 0.455 x total body water (cOkO – cHkH) 172 
 173 
CO2 was used in the modified Weir equation to calculate TEE as: 174 
 175 
TEE (kcal/day) = 22.4 x (1.1 x CO2 + 3.9 x O2) 176 
 177 
where O2 (in liters/day) was calculated by:  178 
 179 
O2 = CO2 ÷ food quotient 180 
 181 
Food quotient was assumed to be 0.86, representative of a typical diet on a population level (33).  182 
Quality control measures to screen for unacceptable estimates included confirming the 183 
following for each patient: 18O enrichment/intercept >0.08, linear fit of 2H and 18O slopes, kO/kH 184 
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1.1 – 1.7, similar residuals of predicted and measured 2H and 18O, and NH/NO 1.0 - 1.7. One 185 
patient provided urine samples for isotope analysis on days 11 and 17 and both were assessed. 186 
Another patient underwent unexpected surgery on day 5 and had 4 days of samples; since all 187 
quality control measures outlined above were met (including kO/kH =1.315 and NH/NO = 1.050) 188 
and our results were similar with and without this patient, the data was kept in the final analyses.  189 
TEE was expressed as kcal/day and kcal/kg body weight measured at the study visit 190 
(same day as isotopic dosing and REE measurement). Predicted TEE was calculated as 25kcal/kg 191 
and 30 kcal/kg body weight based on internationally-accepted clinical oncology guidelines from 192 
the European Society for Clinical Nutrition and Metabolism (15) and from Dietary Reference 193 
Intakes (DRI)(34), using the overweight and obese specific equation where appropriate. For 194 
exploratory purposes, IPAQ categories were used to determine physical activity categories for 195 
the DRI TEE equation as follows: sedentary: IPAQ category 1, low active: IPAQ category 2, 196 
active: IPAQ category 3.  197 
Physical activity  198 
Physical activity level (PAL) was determined as the ratio between TEE and REE. Since 199 
PAL is a ratio method and subject to bias as the regression intercept is not zero (35) (or could be 200 
indicative of a non-linear relationship), activity was also expressed as residual activity-related 201 
energy expenditure (RAEE) (36). This was calculated as the residual from TEE (dependent) and 202 
REE (independent), with positive values being associated with higher-than-average physical 203 
activity and negative numbers being associated with lower-than-average physical activity 204 
(expressed in kcal/day).  205 
Patients were asked to wear ActiCal accelerometers (Phillips Respironics, Bend, OR, 206 
USA) during the 14-day collection period on the right hip. A 15-second epoch length was used. 207 
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Patients were also asked to keep a record of wear times, including time awoken in the morning 208 
and time to bed in the evening. A valid day of monitoring was defined as ≥12 hours of wear time 209 
(37). Only patients with at least four valid days of accelerometer monitoring were included (38). 210 
TEE calculations from ActiCal was also compared to measured TEE.  211 
Medical variables 212 
At the time of assessment, patients were scheduled to begin either radiation, 213 
chemotherapy, combined radiation and chemotherapy, or surveillance. Neutrophil to lymphocyte 214 
ratio from medical records was used as a measure of systemic inflammation; only the value 215 
closest to the study date was assessed in a cross-sectional manner. Prospective weight change 216 
over treatment or surveillance was also acquired from medical records and expressed as %weight 217 
change/100 days to account for varying follow-up appointment dates.  218 
Statistical analysis 219 
All data was assessed using SPSS software, version 24 (IBM Corp., Armonk, NY, USA), 220 
with the threshold for significance set at p ≤ 0.05. Normality in variables was determined using 221 
the Shapiro-Wilk test; non-normally distributed variables were reported as median and 222 
interquartile range (IQR). Effect size for post-hoc sample size analysis was calculated using TEE 223 
data (n=12) at baseline from an ongoing clinical trial in a similar population (39). An effect size 224 
of 0.73 and α 0.05 yielded a power of 0.89 to detect a mean difference of 246 ± 334 kcal/day 225 
between measured versus predicted TEE from the DRI intake recommendation using two-tailed 226 
paired samples t-test.  227 
Pearson correlation coefficients or Spearman’s rank-order correlation (for non-parametric 228 
variables) described relationships between variables. BMI and PAL were split by the sample 229 
median and FM:FFM was split by sex-specific sample median to explore differences in energy 230 
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expenditure. Paired t-tests assessed differences in parameters within individuals. Independent 231 
samples t-tests or Mann-Whitney U-test (when dependent variables were non-normally 232 
distributed for each group of the independent variable) determined differences between patient 233 
groups stratified by sex, previous radiotherapy (yes or no), % REE from predicted, ASMI, PAL 234 
median, RAEE (negative versus positive residuals), BMI median, sex-specific FM:FFM median, 235 
or TEE.  Bland-Altman analyses were used to assess the agreement between measured and 236 
predicted TEE from current energy intake recommendations and ActiCal-derived TEE. Bias 237 
indicates group-level agreement and is the mean difference between predicted minus measured 238 
values. Limits of agreement, or bias ± two standard deviations, indicates agreement for each 239 
individual. Bias and limits of agreement were expressed as percent to account for body size and 240 
individual energy expenditure. Proportional bias was quantified by Pearson correlation 241 
coefficient between mean of measured and predicted TEE and bias were used to determine if 242 
there were trends in the magnitude of bias with increasing TEE.   243 
Results 244 
Patients 245 
Between March 1, 2017 and January 31, 2018, 143 patients with CRC were approached 246 
to participate, with 49 completing REE measurements (39.8% overall accrual). Of those, a total 247 
of 21 patients (14 male) completed the optional doubly labeled water assessments (42.8% accrual 248 
of those who completed basic study measurements), with 20 completing body composition and 249 
accelerometer measurements, Supplementary Figure 1. Patient characteristics are presented in 250 
Table 1. Only one patient had stage IV disease and was not an outlier in terms of energy 251 
expenditure or body composition measurements. All other patients had stage II (n=3, 14.3%) or 252 
stage III (n=17, 80.1%) disease and most individuals presented with overweight (n=8, 38.1%) or 253 
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obesity (n=8, 38.1%). Average previous one-month weight change was -1.5% ± 3.4% (range: -254 
7.9%, 4.9%) and previous six-month weight change was -5.3% ± 5.1% (range: -20.0%, 0%), 255 
with no differences in weight loss between sexes. Seven patients had weight loss >5% in the past 256 
6 months. Four patients had undergone neoadjuvant combined radiotherapy and chemotherapy 257 
(>1 month prior to study inclusion), with two having colon cancer and two having rectal cancer. 258 
There were no differences in anthropometric, demographic, energy expenditure (including PAL), 259 
or body composition variables between those who had received or not received radiotherapy. 260 
Most (n=17) patients had undergone surgery for early stage high risk disease  before (n=10, 261 
median 49 days [IQR: 45 - 65 days] from study visit) or after (n=7, median 102 days [IQR: 95 – 262 
102 days]) the study visit. Since many individuals will experience recurrence after curative 263 
treatment (40) due to the presence of microscopic residual disease after surgery, individuals in 264 
this study were still considered as patients with cancer after surgical resection. Most (n=10, 265 
47.6%) were scheduled to undergo adjuvant chemotherapy with folinic acid, fluorouracil, and 266 
oxaliplatin, with remaining patients scheduled to begin neoadjuvant radiochemotherapy (n=8, 267 
38.1%), neoadjuvant short-course radiotherapy (n=2, 9.5%), or surveillance (n=1, 4.8%).  268 
Patient-reported measures 269 
 Most patients had low scores for all PG-SGA boxes, indicating good nutritional status 270 
and physical function. Most (n=11, 52.4%) scored 0 for weight change. All patients scored 0 271 
(n=9, 42.9%) or 1 (n=12, 57.1%) for food intake. Symptom score was variable (range: 0, 6), with 272 
most (n=13, 61.9%) indicating no symptoms. Within activities and function, most patients 273 
indicated they were “normal with no limitations” (n=10, 47.6%) or “not my normal self, but able 274 
to be up and about with fairly normal activities” (n=9, 42.9%), with two (9.5%) selecting “able to 275 
do little activity and spend most of the day in bed or chair”. Median global quality of life score 276 
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was 75 (IQR: 58.3, 83.3), corresponding to median 5.5 (IQR: 4.5, 6.0) on a scale of 1 to 7.  Self 277 
reported physical activity from IPAQ was highly variable: median walking MET-minutes/week 278 
was 693 (IQR: 396, 2871) and median moderate activity was 900 MET-minutes/week (IQR: 300, 279 
1875). Most (n=17, 81.0%) did not report vigorous activity. Median total reported MET-280 
minutes/week was 1955 (IQR: 1265, 5724). 281 
Anthropometrics and body composition 282 
Anthropometric and body composition variables are presented in Table 1. As expected, 283 
FFM and FFMI were lower in females; however, there were no differences in FM or FMI 284 
between sexes. Median BMI was 28.7 kg/m2 and median FM:FFM was 0.44 in males and 0.63 in 285 
females. 286 
Energy expenditure description  287 
 All measures of TEE from DLW met quality control estimates. Mean tracer elimination 288 
rate (kO/kH) from DLW was normal (1.281 ± 0.050) and 2H2:18O distribution volume (NH/NO) was 289 
1.036 ± 0.018. Males had higher REE and TEE, but not PAL, Table 1. Group median REE was 290 
1698 kcal/day (IQR: 1146, 2009 kcal/day; mean ± standard deviation: 1764 ± 415 kcal/day), 291 
which was higher than the Mifflin St.-Jeor prediction (median [IQR]: 1545 [1411, 1817], P = 292 
0.001). Approximately half (n=11, 52.4%) of patients had hypermetabolism and none had 293 
measured REE <90% of predicted (suggestive of hypometabolism). Patients with 294 
hypermetabolism had lower PAL (1.31 ± 0.22 vs. 1.56 ± 0.26, P = 0.024) and RAEE (-179 ± 318 295 
vs. 196 ± 373 kcal/day from the regression line, P = 0.022). However, percent REE bias was not 296 
correlated to TEE in kcal/day or kcal/kg/day and there were no differences in TEE, percent 297 
previous one-month or six-month weight change between groups; in other words, higher than 298 
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“expected” REE was associated with lower physical activity but did not impact total energy 299 
requirements or weight change.  300 
 Characteristics of TEE and PAL are presented in Table 1. A wide variability in TEE 301 
expressed as kcal/day (range: 1562, 3622) and kcal/kg body weight/day (range: 20.4, 48.5) was 302 
observed. Males had higher absolute TEE than females, although TEE in kcal/kg body weight 303 
and PAL were not different between sexes. Approximately half (n=12, 57.1%) of patients fell 304 
within 25-30 kcal/kg body weight, Figure 1. Median PAL was 1.49 and was also variable, 305 
ranging from 1.04 to 2.16 (mean, standard deviation: 1.43 ± 0.27).  306 
 Relationships between energy expenditure variables and age, body weight, FM, and FFM 307 
are shown in Table 2. REE and TEE were positively correlated to body weight and FFM, with 308 
higher correlations observed with FFM compared to body weight. PAL and RAEE were not 309 
related to any variable. Four patients had low ASMI (all male) and two of these had weight loss 310 
>2% in the previous 6 months (i.e. cachectic). There were no differences in any anthropometric, 311 
energy expenditure, or physical activity variables between individuals with low versus normal 312 
ASMI; these results were the same when only males were assessed. Similarly, only one patient 313 
had FFMI below pre-defined cut-off values, precluding any further comparison.  314 
Agreement with energy recommendation estimations 315 
 Energy recommendations were correlated with measured TEE in all equations (r: 0.548 – 316 
0.826, p: 0.010 – <0.001). Predicted energy recommendation with 25 kcal/kg was lower than 317 
measured TEE (2128 ± 459 vs. 2473 ± 499 kcal/day, P = 0.002), but all other estimations were 318 
not different on a group level, Table 3. However, less than half of patients had TEE within 10% 319 
of all recommendations. Wide limits of agreement were also observed between TEE and all 320 
energy recommendations; for example, even the recommendation with the smallest limits of 321 
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agreement (DRI with measured PAL) under-predicted by up to 22.5% below (484 kcal/day) to 322 
22.7 % above (468 kcal/day) measured TEE, Figure 2. Using assumed PAL from IPAQ 323 
categories did not improve the prediction ability and produced the widest limits of agreement (-324 
33.5, 50.2%, or -742, 1060 kcal/day). No proportional bias was apparent in any recommendation.  325 
 Body weight, FM, and FM:FFM were positively correlated to percent bias using 25 326 
kcal/kg and 30 kcal/kg, Table 4.  PAL and RAEE were negatively correlated to percent bias 327 
from 25 kcal/kg, 30 kcal/kg, DRI with assumed PAL, and ActiCal TEE. Average percent bias 328 
using 25 kcal/kg and 30 kcal/kg was lower (i.e. underestimation) in those with BMI and 329 
FM:FFM below the medians (BMI median: 28.29 kg/m2; FM:FFM median: males: 0.44, 330 
females: 0.63), Figure 3. Bias was frequently lower in those with higher PAL and RAEE, Figure 331 
3. Patients with TEE > 30 kcal/kg (n=7) had lower BMI (24.1 ± 3.3 vs. 30.4 ± 4.2 kg/m2, P < 332 
0.001), higher PAL (1.67 ± 0.23 vs. 1.31 ± 0.20, P = 0.001), and higher RAEE (309 ± 387 vs. -333 
154 ± 291 kcal/day , P = 0.006). REE bias from Mifflin St.-Jeor equations was not related to bias 334 
from TEE equations.  335 
Activity patterns 336 
 Average wear time of the ActiCal devices was 12 ± 3 days, with 20 patients having ≥ 4 337 
days of wear time and at least one weekend (2 days) available. Total IPAQ score was not 338 
correlated to any measure of energy expenditure and no other correlations between activity and 339 
body composition, physical function, or quality of life was observed. Clinical parameters 340 
 Average weight change during treatment was -2.4 ± 5.2%/100 days and was not 341 
associated with any energy expenditure, body composition, or physical activity variables. 342 
Average neutrophil to lymphocyte ratio was 3.4 ± 2.2 with a range of 1.29 to 9.33 and was also 343 
not associated with any other variable.  344 
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Discussion 345 
 This study is the first to measure TEE in free living conditions in patients with primarily 346 
earlier stage CRC.  TEE and PAL were higher than previously reported and were greatly 347 
variable. Current energy intake recommendations (15,34) did not reflect TEE in this cohort. Such 348 
discrepancies were due to highly variable body composition and PAL, the latter of which cannot 349 
accurately be estimated by patient recall.  350 
 As screening and treatment modalities continue to improve, it is expected that more 351 
patients will be diagnosed at earlier stages of cancer with longer expected survival; therefore, 352 
understanding differences in energy requirements in different cohorts of patients (i.e. early 353 
versus late stages or by cancer type) is important for optimal nutritional care. However, our 354 
current knowledge relies primarily on patients with cachexia and/or advanced disease, which 355 
might be unrepresentative of many patients with CRC. The largest study to date that objectively 356 
measured TEE using DLW included 24 cachectic patients with advanced pancreatic cancer who 357 
had an average BMI of 20 kg/m2 and 19% pre-illness weight loss (7). Average REE was higher 358 
and TEE was lower than predicted; average PAL was 1.24 ± [standard error] 0.04 at baseline. 359 
Others have reported overall low PAL (8) and TEE (6) and that structured exercise can increase 360 
TEE (9) in sample sizes ranging from four to eight patients with various cancer types. Average 361 
PAL of our sample was 1.43 ± 0.27, which is higher than previously reported in oncology (7,8); 362 
this value corresponds to a “low active” lifestyle (34) and is slightly lower than reported in 363 
healthy individuals (PAL 1.6) (41). Compared to previous research (6,7), patients in the current 364 
sample had generally earlier stage disease, less weight loss, lower incidence of low ASMI and 365 
low FFMI. Notably, CRC is associated with lower incidence of weight/loss cachexia compared 366 
to other cancer types (e.g. pancreatic, lung, gastric cancer) (42). Most individuals in this study 367 
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also had adequate physical function and PAL was highly variable. In advanced, cachectic 368 
patients, higher REE and lower TEE may indicate an adaptive response to narrow the gap 369 
between TEE and reduced energy intake or a reflection of low physical activity secondary to the 370 
disease and its associated side effects (7), which may not occur in earlier stage CRC. Our 371 
findings are novel and suggest that energy metabolism - and therefore energy requirements - 372 
differs greatly according to cancer site and stage. Further exploration of the determinants of TEE 373 
and PAL according to cancer site and stage is warranted.  374 
We found that energy intake recommendations based on body weight alone were poor 375 
assessments of actual energy requirements (assumed to be equal to TEE), with individual 376 
differences ranging from -1613 kcal/day (or 48.5%) underprediction with 25 kcal/kg body 377 
weight/day to 968 kcal/day (or 46.9%) overprediction with 30 kcal/kg body weight/day.. 378 
Additionally, a small proportion of energy requirement predictions fell within 10% of measured 379 
TEE, ranging from 33.3% using 25 kcal/kg/day to 47.6% using DRI with measured PAL and 380 
DRI with assumed PAL. This proportion is smaller than previous reports in healthy adults (62.9 - 381 
85.7%)(43,44), suggesting that cancer impacts TEE in ways not captured by current energy 382 
recommendations.  383 
We found that bias using body weight-based equations was positively related to body 384 
weight and composition (i.e. higher body weight, FM, and higher FM:FFM related to over-385 
prediction). Since obesity is a risk factor for several cancers (including CRC) (45,46), a large 386 
number of individuals have obesity at diagnosis (47). However, low FFM is apparent at 387 
diagnosis independent of body weight and FM and is not a condition exclusive to advanced 388 
cancer (2). Energy recommendations might therefore have widespread error within oncology, 389 
although further research in other populations is required.    390 
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While previous research suggests that TEE might be lower in the presence of high REE 391 
(7), this was not apparent in the current study. Assuming an altered TEE based on REE alone or 392 
by applying a universal activity and/or energy factor to measured or estimated REE likely 393 
introduces substantial bias in energy recommendations. Several previous studies have 394 
investigated REE in patients with CRC (48–52) or mixed tumor types (53,54). However, many 395 
of these were limited in their interpretation of REE in relation to body composition since REE 396 
was often divided by measures of muscularity (e.g. FFM), which creates a statistical bias 397 
wherein smaller individuals will appear to have higher REE per kilogram of FFM (i.e. patients 398 
with low body weight or cachexia might have an artificially high REE), as we (55) and others 399 
(56–58) have discussed. Nevertheless, these studies collectively suggest that REE and body 400 
composition might differ according to tumor site (53,59,60) and relates to cancer stage and 401 
systemic inflammation (51,61). While neutrophil:lymphocyte was not associated with energy 402 
metabolism in the present analyses, more sensitive indices of systemic inflammation (i.e. C-403 
reactive protein, interleukin-6, tumor necrosis factor-α) might relate to TEE and PAL and should 404 
be investigated in more depth. The current study builds upon this line of investigation and 405 
provides new evidence that body composition and physical activity might also relate to energy 406 
requirements to a greater degree than “high” REE. Equations that incorporate body composition 407 
and physical activity and that are developed from oncology populations would likely be more 408 
accurate, although further research on the feasibility and accuracy of such approaches is needed.  409 
Physical activity is highly variable in healthy individuals and can significantly impact 410 
TEE. In the present study, PAL variability was similar than that of sedentary to lightly-active 411 
healthy adults (34,62). According to our data, it appears that physical activity also greatly 412 
impacted energy requirements in these patients and was the most variable component of TEE. 413 
21 
 
However, subjective measures of physical activity (IPAQ) did not improve estimation of energy 414 
requirements and were not related to any physical or clinical measure. This is likely because 415 
physical activity is often over- or under-reported (63,64) and is therefore a poor reflection of 416 
actual physical activity engagement. Since physical activity is feasible, safe, and beneficial for 417 
patients with cancer (65–67) and impacts energy requirements, improved techniques for 418 
capturing this modality are needed. 419 
While this is the largest exploratory study of TEE in earlier stage cancer and CRC using 420 
several accurate techniques, there are inherent limitations. Firstly, DLW measures TEE over a 421 
span of only two weeks. The impact of anti-cancer therapy (and associated side effects), body 422 
composition changes, or disease progression on TEE and physical activity patterns cannot be 423 
assumed, but should be investigated in more depth. Although our sample size was sufficient to 424 
detect differences in predicted and measured TEE from the DRI equation, the variability in 425 
equation error should be confirmed in samples with larger numbers of individuals and with 426 
different tumor types (as energy metabolism might presumably vary in this regard).   427 
 In conclusion, TEE and physical activity were highly variable in patients with CRC, 428 
which was not apparent in current energy recommendations on an individual level. TEE differed 429 
according to categories of body weight, body composition, and physical activity; these variables 430 
also impacted error associated with energy recommendations. Future research should therefore 431 
characterize the feasibility and impact of incorporating body composition and physical activity in 432 
the estimation of energy requirements for patients with cancer. 433 
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Table 1. Characteristics of 21 patients with colorectal cancer1 
Characteristic Total (n=21)2 Males (n=14) Females (n=7) P value3 
Age, years 57 ± 12 
(34 – 73) 
55 ± 13 
(34 – 72) 
59 ± 13 
(40 – 73) 
0.582 
Body weight, kg 85.1 ± 18.4 
(54.3 – 131.1) 
91.5 ± 17.3 
(68.6 – 131.1) 
72.5 ± 14.0 
(54.3 – 92.6) 
0.021 
Body mass index, kg/m2 28.3 ± 4.9 
(20.9 – 39.5) 
29.2 ± 4.9 
(20.9 – 39.5) 
26.7 ± 4.9 
(22.0 – 35.0) 
0.294 
Fat mass, kg 28.8 ± 12.3 
(9.9 – 59.8) 
29.5 ± 13.8 
(9.9 – 59.8) 
27.6 ± 9.6 
(16.5 – 41.4) 
0.754 
Fat mass index, kg/m2 9.6 ± 3.8 
(3.1 – 18.0) 
9.3 ± 13.8 
(3.1 – 18.0) 
10.1 ± 3.4 
(6.3 – 15.1) 
0.651 
Percent fat 32.9 ± 8.7 
(14.7 – 45.6) 
30.6 ± 9.1 
(14.7 – 45.6) 
37.3 ± 6.3 
(27.6 – 44.4) 
0.101 
Fat-free mass, kg 56.3 ± 10.7 
(37.6 – 74.1) 
62.6 ± 6.8 
(48.1 – 74.1) 
44.6 ± 5.1 
(37.6 – 51.8) 
<0.001 
Fat-free mass index, 
kg/m2 
18.6 ± 2.4 
(14.1 – 22.2) 
19.8 ± 1.8 
(16.5 – 22.2) 
16.5 ± 1.9 
(14.1 – 19.8) 
0.001 
Fat mass:fat-free mass 0.51 ± 0.19 
(0.17 – 0.84) 
0.46 ± 0.19 
(0.17 – 0.84) 
0.61 ± 0.16 
(0.38 – 0.80) 
0.102 
Appendicular skeletal 
muscle, kg 
24.4 ± 6.4 
(16.2 – 42.6) 
27.5 ± 5.6 
(20.3 – 42.6) 
18.5 ± 2.1 
(16.2 – 21.4) 
0.001 
Appendicular skeletal 
muscle index, kg/m2 
7.9 ± 1.5 
(5.7 – 12.3) 
8.5 ± 1.5 
(6.9 – 12.3) 
6.9 ± 0.9 
(5.7 – 8.4) 
0.018 
Resting energy 
expenditure, kcal/day 
1698  
(IQR: 1446 – 2009) 
1841  
(IQR: 1668 – 2077) 
1423  
(IQR: 1388 – 1500) 
<0.001 
Respiratory quotient  0.80 ± 0.05 
(0.73 – 0.93) 
0.81 ± 0.05 
(0.73 – 0.93) 
0.79 ± 0.03 
(0.74 – 0.82) 
0.393 
Total energy expenditure, 
kcal/day 
2473 ± 499 
(1562 – 3622) 
2646 ± 490 
(1929 – 3622) 
2127 ± 313 
(1562 – 2509) 
0.020 
Total energy expenditure, 
kcal/kg body weight 
29.7 ± 6.3 
(20.4 – 48.5) 
29.7 ± 7.1 
(20.4 – 48.5) 
29.8 ± 4.8 
(25.1 – 36.1) 
0.952 
Physical activity level 1.43 ± 0.27 
(1.04 – 2.16) 
1.40 ± 0.29 
(1.04 – 2.16) 
1.49 ± 0.22 
(1.04 – 1.76) 
0.463 
1Presented as mean ± and standard deviation (range) or median (interquartile [IQR] range) for 
non-normality between groups. Physical activity level is total energy expenditure:resting energy 
expenditure.  
2n=20 total and n=13 males with body composition measurements  
3All differences tested using independent samples t-test except in the case of non-normality 
wherein Mann-Whitney U-test was utilized. 
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Table 2. Correlations between energy expenditure, demographic and body composition 
variables (n=21)1 
 Age Weight FM FFM FM:FFM 
Resting energy expenditure2 -0.353 0.729* 0.388 0.873* -0.029 
Total energy expenditure -0.382 0.558* 0.350 0.658* 0.025 
Physical activity level 0.163 -0.366 -0.396 -0.255 -0.273 
RAEE 0.083 0.050 -0.093 0.213 -0.197 
1Numbers are r values. *P < 0.05, correlation. FM:FFM: fat mass:fat-free mass; RAEE: residual 
activity energy expenditure (residual from total energy expenditure and resting energy 
expenditure) 
2Spearman’s rank-order correlation; all other values derived from Pearson correlation 
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Table 3. Agreement between measured and estimated total energy expenditure (TEE) (n=21)1 
 Mean ± SD, 
kcal/day 
Percent 
bias, mean 
± SD 
Proportional 
bias2 
LOA, % Absolute 
LOA, % 
Minimum 
difference, 
% 
Maximum 
difference, 
% 
Within 10% 
measured 
TEE, n (%) 
   r P      
Measured TEE 2473 ± 499         
25 kcal/kg 2128 ± 459* -12.6 ± 16.5 -0.099 0.670 -45.1, 19.8 64.9 -48.5 22.4 7 (33.3) 
30 kcal/kg 2554 ± 551 4.8 ± 19.9 0.120 0.604 -34.1, 43.8 77.8 -38.2 46.9 8 (38.1) 
DRI – measured PAL 2554 ± 495 4.1 ± 12.9 -0.012 0.958 -21.2, 29.3 50.5 -22.5 22.7 10 (47.6) 
DRI – assumed PAL 2632 ± 510 8.3 ± 21.4 0.029 0.901 -33.5, 50.2 83.8 -22.5 48.9 10 (47.6) 
ActiCal 2359 ± 549 -4.6 ± 19.5 0.125 0.600 -42.7, 33.6 76.3 -35.1 43.3 9 (42.9) 
1DRI, dietary reference intake; LOA, limits of agreement; PAL, physical activity level. *P ≤ 0.05 difference between measured TEE 
and energy intake recommendations via paired samples t-test.  
2Proportional bias determined as Pearson correlation between bias and mean of measured and predicted TEE.  
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Table 4. Correlation of percent bias between total energy expenditure and estimations with patient 
characteristics (n=21)1 
 Age Weight FM FFM FM:FFM PAL RAEE 
25 kcal/kg 0.133 0.509* 0.586* 0.285 0.507* -0.767* -0.722* 
30 kcal/kg 0.133 0.509* 0.586* 0.285 0.507* -0.767* -0.722* 
DRI – measured PAL -0.240 -0.008 -0.225 0.245 -0.410 -0.344 -0.384 
DRI – assumed PAL -0.194 0.187 0.084 0.290  -0.085 -0.791* -0.760* 
ActiCal -0.107 0.478* 0.429 0.380 0.297 -0.631* -0.587* 
1Percent bias calculated as (energy intake recommendation - total energy expenditure / total energy expenditure) x 100.  
FFM, fat-free mass; FM, fat mass; PAL, physical activity level; RAEE: residual activity energy expenditure (residual from total 
energy expenditure and resting energy expenditure) 
*P < 0.05, Pearson correlation 
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Figure legends 
Figure 1. Range of measured total energy expenditure (TEE) in kcal/kg body weight in 21 
patients with colorectal cancer. Each point is a patient. The box represents current 
recommendations of 25-30 kcal/kg body weight from the European Society for Clinical Nutrition 
and Metabolism (Arends et al. Clin Nutr. 2017; 36[5]:1187-96) (15). 
Figure 2. Bland-Altman plots of measured versus predicted total energy expenditure (TEE) 
in 21 patients with colorectal cancer. The middle solid line represents bias (mean difference 
between measured and predicted TEE) and the two parallel dotted lines represent the 95% limits 
of agreement (bias ± 2 standard deviations). Proportional bias was determined as Pearson 
correlation coefficient between mean of measured and predicted TEE and bias; no proportional 
bias was apparent in any recommendation. DRI, dietary reference intakes; PAL, physical activity 
level, measured as TEE:resting energy expenditure. DRI was calculated using measured PAL 
and estimated from a subjective questionnaire.  
Figure 3. Percent bias of predicted minus measured total energy expenditure according to 
median of body mass index (A), fat mass:fat-free mass (FM:FFM)(B), physical activity level 
(PAL)(C), and residual activity energy expenditure (RAEE)(D). *p≤0.05, independent 
samples t-test. aPAL, assumed PAL from subjective questionnaire; DRI, dietary reference intake; 
mPAL, measured physical activity level. N=21. Data are presented as mean ± standard error of 
the mean. 
 
 
 
